Molecular markers of pancreatic cancer: Development and clinical relevance

Langenbeck's Archives of Surgery

Volumn 393, Issue 6, 2008, Pages 883-890

  Fry, Lucia C ^a   Mönkemüller, Klaus ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

CA 19 9; DNA methylation; K ras; Mitochondrial mutations; Molecular markers; Pancreatic cancer; Proteomics

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; K RAS PROTEIN; MOLECULAR MARKER; MUCIN; PROTEIN P16; PROTEIN P53; PYRUVATE KINASE; TELOMERASE; TRANSFORMING GROWTH FACTOR; VASCULOTROPIN;

DNA METHYLATION; DNA MICROARRAY; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; TUMOR SUPPRESSOR GENE;

ALGORITHMS; CA-19-9 ANTIGEN; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, MITOCHONDRIAL; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 53549105536     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-007-0276-0     Document Type: Review

References (88)

1. AL Warshaw C Fernandez-del Castillo 1992 Pancreatic carcinoma N Engl J Med 326 455 465
2. American Gastroenterological Association, medical position statement 1999 Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma Gastroenterology 117 1463 1484
3. C Rosty M Goggins 2002 Early detection of pancreatic carcinoma Hematol Oncol Clin North Am 16 37 52
4. A Oto MA Eltorky A Dave RD Ernst K Chen B Rampy G Chaljub W Nealon 2006 Mimicks of pancreatic malignancy in patients with chronic pancreatitis: correlation of computed tomography imaging features with histopathologic findings Curr Probl Diagn Radiol 35 199 205
5. M Goggins 2005 Molecular markers of early pancreatic cancer J Clin Oncol 23 4524 4531
6. D Li K Xie R Wolff JL Abbruzzese 2004 Pancreatic cancer Lancet 363 1049 1057
7. R Talar-Wojnarowska E Malecka-Panas 2006 Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications Med Sci Monit 12 RA186 RA193
8. Seufferlein T, Adler G (2005) What can be expected from tumor markers in pancreatic cancer. In: Dominguez-Muñoz JE (ed) Clinical pancreatology for practising gastroenterologist and surgeons. Blackwell, Malden, pp 377-382
9. MA Eloubeidi VK Chen IA Eltoum D Jhala DC Chhieng N Jhala SM Vickers CM Wilcox 2003 Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications Am J Gastroenterol 98 2663 2668
10. A Khalid L Nodit M Zahid K Bauer D Brody SD Finkelstein KM McGrath 2006 Endoscopic ultrasound fine needle aspirate DNA analysis to differentiate malignant and benign pancreatic masses Am J Gastroenterol 101 2493 2500
11. RH Hruban M Goggins J Parsons SE Kern 2000 Progression model for pancreatic cancer Clin Cancer Res 6 2969 2972
12. G Cwik G Wallner T Skoczylas A Ciechanski K Zinkiewicz 2006 Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions Arch Surg 141 968 973
13. N Sawabu H Watanabe Y Yamaguchi K Ohtsubo Y Motoo 2004 Serum tumor markers and molecular biological diagnosis in pancreatic cancer Pancreas 28 263 267
14. S Boeck P Stieber S Holdenrieder R Wilkowski V Heinemann 2006 Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer Oncology 70 255 264
15. MA Tempero E Uchida H Takasaki DA Burnett Z Steplewski PM Pour 1987 Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer Cancer Res 47 5501 5503
16. H Koprowski M Brockhaus M Blaszczyk J Magnani Z Steplewski V Ginsburg 1982 Lewis blood-type may affect the incidence of gastrointestinal cancer Lancet 1 1332 1333
17. W Steinberg 1990 The clinical utility of the CA 19-9 tumor-associated antigen Am J Gastroenterol 85 350 355
18. F Safi W Schlosser G Kolb HG Beger 1997 Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms J Gastrointest Surg 1 106 112
19. EP DiMagno HA Reber MA Tempero 1999 AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma: American Gastroenterological Association Gastroenterology 117 1464 1484
20. A Tomazic V Pegan 2000 Preoperative staging of periampullar cancer with US, CT, EUS and CA 19-9 Hepatogastroenterology 47 1135 1137
21. A DelMaschio A Vanzulli S Sironi M Castrucci R Mellone C Staudacher M Carlucci A Zerbi D Parolini A Faravelli 1991 Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy Radiology 178 95 99
22. EM Yoshida CH Scudamore SR Erb DA Owen HK Silver 1995 Markedly elevated serum CA 19-9 levels in a case of chronic pancreatitis Can J Surg 38 83 86
23. J Glenn WM Steinberg SH Kurtzman SM Steinberg WF Sindelar 1988 Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas J Clin Oncol 6 462 468
24. XT Jiang HQ Tao SC Zou 2004 Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer Hepatobiliary Pancreat Dis Int 3 464 468
25. RC Montgomery JP Hoffman LB Riley A Rogatko JA Ridge BL Eisenberg 1997 Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas Ann Surg Oncol 4 551 556
26. F Safi W Schlosser S Falkenreck HG Beger 1998 Prognostic value of CA 19-9 serum course in pancreatic cancer Hepatogastroenterology 45 253 259
27. C Sperti C Pasquali S Catalini F Cappellazzo B Bonadimani R Behboo S Pedrazzoli 1993 CA 19-9 as a prognostic index after resection for pancreatic cancer J Surg Oncol 52 137 141
28. J Lundin PJ Roberts P Kuusela C Haglund 1994 The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer Br J Cancer 69 515 519
29. A Katz A Hanlon R Lanciano J Hoffman L Coia 1998 Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy Int J Radiat Oncol Biol Phys 41 393 396
30. C Bassi R Salvia AA Gumbs G Butturini M Falconi P Pederzoli 2002 The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, CA 19-9, CA 125, CA 15-3 Langenbecks Arch Surg 387 281 285
31. RW Talbot DM Nagorney JH Pemberton HS Wieand RE Ritts Jr 1989 Comparison of portal and peripheral blood levels of carcinoembryonic antigen, CA 19-9, and CA 125 tumor-associated antigens in patients with colorectal and pancreatic cancer Cancer Res 49 542 543
32. MP Liu XZ Guo JH Xu D Wang HY Li ZM Cui JJ Zhao LN Ren 2005 New tumor-associated antigen SC6 in pancreatic cancer World J Gastroenterol 11 7671 7675
33. Lluis F (2005) Genetic bases of pancreatic carcinogenesis: which concepts may be clinically relevant. In: Dominguez-Muñoz JE (ed) Clinical pancreatology for practising gastroenterologist and surgeons. Blackwell, Malden, pp 359-365
34. C Almoguera D Shibata K Forrester J Martin N Arnheim M Perucho 1988 Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes Cell 53 549 554
35. VT Smit AJ Boot AM Smits GJ Fleuren CJ Cornelisse JL Bos 1988 KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas Nucleic Acids Res 16 7773 7782
36. P Berthelemy M Bouisson J Escourrou N Vaysse JL Rumeau L Pradayrol 1995 Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer Ann Intern Med 123 188 191
37. FA Wenger J Zieren FJ Peter CA Jacobi JM Muller 1999 K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis Langenbecks Arch Surg 384 181 186
38. L Trumper M Menges H Daus D Kohler JO Reinhard M Sackmann C Moser A Sek G Jacobs M Zeitz M Pfreundschuh 2002 Low sensitivity of the ki-ras polymerase chain reaction for diagnosing pancreatic cancer from pancreatic juice and bile: a multicenter prospective trial J Clin Oncol 20 4331 4337
39. T Yamada S Nakamori H Ohzato S Oshima T Aoki N Higaki K Sugimoto K Akagi Y Fujiwara I Nishisho M Sakon M Gotoh M Monden 1998 Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features Clin Cancer Res 4 1527 1532
40. SR Bramhall 1998 The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis Int J Pancreatol 23 83 100
41. K Takahashi K Yamao K Okubo A Sawaki N Mizuno R Ashida T Koshikawa Y Ueyama K Kasugai S Hase S Kakumu 2005 Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA Gastrointest Endosc 61 76 79
42. M Arvanitakis JL Van Laethem J Parma V De Maertelaer M Delhaye J Deviere 2004 Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation Endoscopy 36 535 542
43. N Teich J Mossner 2004 Molecular analysis of pancreatic juice: a helpful tool to differentiate benign and malignant pancreatic tumors? Dig Dis 22 235 238
44. J Boadas J Mora E Urgell P Puig M Roca X Cusso G Capella F Lluis A Farre 2001 Clinical usefulness of K-ras gene mutation detection and cytology in pancreatic juice in the diagnosis and screening of pancreatic cancer Eur J Gastroenterol Hepatol 13 1153 1159
45. J Kim HA Reber SM Dry D Elashoff SL Chen N Umetani M Kitago OJ Hines KK Kazanjian S Hiramatsu AJ Bilchik S Yong M Shoup DS Hoon 2006 Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins Gut 55 1598 1605
46. M Schutte RH Hruban J Geradts R Maynard W Hilgers SK Rabindran CA Moskaluk SA Hahn I Schwarte-Waldhoff W Schmiegel SB Baylin SE Kern JG Herman 1997 Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas Cancer Res 57 3126 3130
47. RE Wilentz J Geradts R Maynard GJ Offerhaus M Kang M Goggins CJ Yeo SE Kern RH Hruban 1998 Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression Cancer Res 58 4740 4744
48. K Ohtsubo H Watanabe Y Yamaguchi YX Hu Y Motoo T Okai N Sawabu 2003 Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters J Gastroenterol 38 663 671
49. MS Redston C Caldas AB Seymour RH Hruban L da Costa CJ Yeo SE Kern 1994 p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions Cancer Res 54 3025 3033
50. DG Kirsch MB Kastan 1998 Tumor-suppressor p53: implications for tumor development and prognosis J Clin Oncol 16 3158 3168
51. G Casey Y Yamanaka H Friess MS Kobrin ME Lopez M Buchler HG Beger M Korc 1993 p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis Cancer Lett 69 151 160
52. PD Sturm RH Hruban TB Ramsoekh LA Noorduyn GN Tytgat DJ Gouma GJ Offerhaus 1998 The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region J Pathol 186 247 253
53. M Yokoyama Y Yamanaka H Friess M Buchler M Korc 1994 p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness Anticancer Res 14 2477 2483
54. L Costentin P Pages M Bouisson P Berthelemy L Buscail J Escourrou L Pradayrol N Vaysse 2002 Frequent deletions of tumor suppressor genes in pure pancreatic juice from patients with tumoral or nontumoral pancreatic diseases Pancreatology 2 17 25
55. N Suehara K Mizumoto M Tanaka H Niiyama K Yokohata Y Tominaga H Shimura T Muta N Hamasaki 1997 Telomerase activity in pancreatic juice differentiates ductal carcinoma from adenoma and pancreatitis Clin Cancer Res 3 2479 2483
56. M Tsutsumi T Tsujiuchi O Ishikawa T Majima M Yoshimoto Y Sasaki T Fukuda H Oohigashi Y Konishi 1997 Increased telomerase activities in human pancreatic duct adenocarcinomas Jpn J Cancer Res 88 971 976
57. N Suehara K Mizumoto M Kusumoto H Niiyama T Ogawa K Yamaguchi K Yokohata M Tanaka 1998 Telomerase activity detected in pancreatic juice 19 months before a tumor is detected in a patient with pancreatic cancer Am J Gastroenterol 93 1967 1971
58. K Ohuchida K Mizumoto N Ishikawa N Sato E Nagai K Yamaguchi H Takaishi T Ide M Tanaka 2004 A highly sensitive and quantitative telomerase activity assay with pancreatic juice is useful for diagnosis of pancreatic carcinoma without problems due to polymerase chain reaction inhibitors: analysis of 100 samples of pancreatic juice from consecutive patients Cancer 101 2309 2317
59. K Seki T Suda Y Aoyagi S Sugawara M Natsui H Motoyama Y Shirai T Sekine H Kawai Y Mita N Waguri T Kuroiwa M Igarashi H Asakura 2001 Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification Clin Cancer Res 7 1976 1981
60. K Mizumoto M Tanaka 2005 Detection of telomerase activity in patients with pancreatic cancer Methods Mol Med 103 199 205
61. K Ohuchida K Mizumoto D Yamada H Yamaguchi H Konomi E Nagai K Yamaguchi M Tsuneyoshi M Tanaka 2006 Quantitative analysis of human telomerase reverse transcriptase in pancreatic cancer Clin Cancer Res 12 2066 2069
62. Y Yamanaka H Friess MS Kobrin M Buchler HG Beger M Korc 1993 Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness Anticancer Res 13 565 569
63. M Juhasz B Nitsche P Malfertheiner MP Ebert 2003 Implications of growth factor alterations in the treatment of pancreatic cancer Mol Cancer 2 5
64. Wirtz M, Nyarangi J, Köninger J, Friess H (2005) Molecular basis of pancreatic carcinogenesis: which concepts may be clinically relevant. In: Dominguez-Muñoz JE (ed) Clinical pancreatology for practising gastroenterologist and surgeons. Blackwell, Malden, pp 351-358
65. H Friess Y Yamanaka M Buchler M Ebert HG Beger LI Gold M Korc 1993 Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival Gastroenterology 105 1846 1856
66. M Korc B Chandrasekar Y Yamanaka H Friess M Buchier HG Beger 1992 Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha J Clin Invest 90 1352 1360
67. GJ Strous J Dekker 1992 Mucin-type glycoproteins Crit Rev Biochem Mol Biol 27 57 92
68. C Balague G Gambus C Carrato N Porchet JP Aubert YS Kim FX Real 1994 Altered expression of MUC2, MUC4, and MUC5 mucin genes in pancreas tissues and cancer cell lines Gastroenterology 106 1054 1061
69. M Andrianifahanana N Moniaux BM Schmied J Ringel H Friess MA Hollingsworth MW Buchler JP Aubert SK Batra 2001 Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance Clin Cancer Res 7 4033 4040
70. H Han DJ Bearss LW Browne R Calaluce RB Nagle DD Von Hoff 2002 Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray Cancer Res 62 2890 2896
71. SR Hustinx D Cao A Maitra N Sato ST Martin D Sudhir C Iacobuzio-Donahue JL Cameron CJ Yeo SE Kern M Goggins J Mollenhauer A Pandey RH Hruban 2004 Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression Cancer Biol Ther 3 1254 1261
72. CA Iacobuzio-Donahue R Ashfaq A Maitra NV Adsay GL Shen-Ong K Berg MA Hollingsworth JL Cameron CJ Yeo SE Kern M Goggins RH Hruban 2003 Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies Cancer Res 63 8614 8622
73. N Sato A Maitra N Fukushima NT van Heek H Matsubayashi CA Iacobuzio-Donahue C Rosty M Goggins 2003 Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma Cancer Res 63 4158 4166
74. DM McCarthy A Maitra P Argani AE Rader DO Faigel NT Van Heek RH Hruban RE Wilentz 2003 Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases Appl Immunohistochem Mol Morphol 11 238 243
75. CA Iacobuzio-Donahue A Maitra GL Shen-Ong T van Heek R Ashfaq R Meyer K Walter K Berg MA Hollingsworth JL Cameron CJ Yeo SE Kern M Goggins RH Hruban 2002 Discovery of novel tumor markers of pancreatic cancer using global gene expression technology Am J Pathol 160 1239 1249
76. K Honda Y Hayashida T Umaki T Okusaka T Kosuge S Kikuchi M Endo A Tsuchida T Aoki T Itoi F Moriyasu S Hirohashi T Yamada 2005 Possible detection of pancreatic cancer by plasma protein profiling Cancer Res 65 10613 10622
77. S Bhattacharyya ER Siegel GM Petersen ST Chari LJ Suva RS Haun 2004 Diagnosis of pancreatic cancer using serum proteomic profiling Neoplasia 6 674 686
78. J Shen MD Person J Zhu JL Abbruzzese D Li 2004 Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry Cancer Res 64 9018 9026
79. J Koopmann P Buckhaults DA Brown ML Zahurak N Sato N Fukushima LJ Sokoll DW Chan CJ Yeo RH Hruban SN Breit KW Kinzler B Vogelstein M Goggins 2004 Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers Clin Cancer Res 10 2386 2392
80. J Koopmann CN Rosenzweig Z Zhang MI Canto DA Brown M Hunter C Yeo DW Chan SN Breit M Goggins 2006 Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9 Clin Cancer Res 12 442 446
81. A Maitra Y Cohen SE Gillespie E Mambo N Fukushima MO Hoque N Shah M Goggins J Califano D Sidransky A Chakravarti 2004 The human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection Genome Res 14 812 819
82. DF Peng Y Kanai M Sawada S Ushijima N Hiraoka S Kitazawa S Hirohashi 2006 DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas Carcinogenesis 27 1160 1168
83. T Ueki M Toyota T Sohn CJ Yeo JP Issa RH Hruban M Goggins 2000 Hypermethylation of multiple genes in pancreatic adenocarcinoma Cancer Res 60 1835 1839
84. SR Hustinx LM Leoni CJ Yeo PN Brown M Goggins SE Kern RH Hruban A Maitra 2005 Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion Mod Pathol 18 959 963
85. N Fukushima KM Walter T Uek N Sato H Matsubayashi JL Cameron RH Hruban M Canto CJ Yeo M Goggins 2003 Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice Cancer Biol Ther 2 78 83
86. H Matsubayashi M Canto N Sato A Klein T Abe K Yamashita CJ Yeo A Kalloo R Hruban M Goggins 2006 DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease Cancer Res 66 1208 1217
87. S Mazurek CB Boschek F Hugo E Eigenbrodt 2005 Pyruvate kinase type M2 and its role in tumor growth and spreading Semin Cancer Biol 15 300 308
88. M Ventrucci A Cipolla C Racchini R Casadei P Simoni L Gullo 2004 Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer Dig Dis Sci 49 1149 1155